SMHG.F Stock Overview
Engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Simcere Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.69 |
| 52 Week High | HK$0.76 |
| 52 Week Low | HK$0.69 |
| Beta | 0.46 |
| 11 Month Change | 0% |
| 3 Month Change | -8.74% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -8.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| SMHG.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 2.2% |
| 1Y | n/a | 10.0% | 31.7% |
Return vs Industry: Insufficient data to determine how SMHG.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SMHG.F performed against the US Market.
Price Volatility
| SMHG.F volatility | |
|---|---|
| SMHG.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SMHG.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SMHG.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 7,027 | Jinsheng Ren | www.simcere.com |
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, a simnotrelvir tablets/ritonavir tablets.
Simcere Pharmaceutical Group Limited Fundamentals Summary
| SMHG.F fundamental statistics | |
|---|---|
| Market cap | US$1.77b |
| Earnings (TTM) | US$98.84m |
| Revenue (TTM) | US$913.72m |
17.9x
P/E Ratio1.9x
P/S RatioIs SMHG.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SMHG.F income statement (TTM) | |
|---|---|
| Revenue | CN¥6.61b |
| Cost of Revenue | CN¥1.62b |
| Gross Profit | CN¥4.98b |
| Other Expenses | CN¥4.27b |
| Earnings | CN¥714.76m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.28 |
| Gross Margin | 75.43% |
| Net Profit Margin | 10.82% |
| Debt/Equity Ratio | 16.9% |
How did SMHG.F perform over the long term?
See historical performance and comparison